Drug Trial Radar · NCT06431243
A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
May 8, 2024
Primary completion
May 1, 2026
Study completion Nov 1, 2026
Sponsor
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives Phase Ib To evaluate the safety and tolerability of Purinostat Mesylate in combination therapy for advanced solid tumors; and to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of Purinostat Mesylate in combination therapy in patients with advanced solid tumors. To determine the recommended Phase II dose (RP2D) of Purinostat Mesylate in combination therapy for advanced solid tumors. Phase IIa To further evaluate the preliminary efficacy of Purinostat Mesylate in combination therapy in patients with advanced solid tumors. Secondary Objectives Phase Ib To evaluate the safety and tolerability of Purinostat Mesylate Monotherapy for the treatment of advanced solid tumors; To evaluate the preliminary efficacy of Purinostat Mesylate in combination therapy in patients with advanced solid tumors; To evaluate the pharmacokinetic characteristics of Purinostat Mesylate in combination therapy for the treatment of advanced solid tumors. Phase IIa To further evaluate the safety and tolerability of Purinostat Mesylate in combination therapy for advanced solid tumors. To evaluate the pharmacokinetic characteristics of Purinostat Mesylate in combination therapy for advanced solid tumors. Exploratory Objectives To assess the pharmacodynamic characteristics in Purinostat Mesylate combination therapy for advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
A0/B0 group Purinostat Mesylate 11.2mg/m2Drug
Purinostat Mesylate 11.2mg/m2
A0/B0 group Purinostat Mesylate 15mg/m2Drug
Purinostat Mesylate 15mg/m2
A group Purinostat Mesylate 6mg/m2Drug
Purinostat Mesylate 6mg/m2 + FS 500mg
A group Purinostat Mesylate 8.4mg/m2Drug
Purinostat Mesylate 8.4mg/m2 + FS 500mg
A group Purinostat Mesylate 11.2mg/m2Drug
Purinostat Mesylate 11.2mg/m2 + FS 500mg
A group Purinostat Mesylate 15 mg/m2Drug
Purinostat Mesylate 15 mg/m2 + FS 500mg
B group Purinostat Mesylate 6 mg/m2Drug
Purinostat Mesylate 6mg/m2 + Tislelizumab 200mg
B group Purinostat Mesylate 8.4 mg/m2Drug
Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg
B group Purinostat Mesylate 11.2mg/m2Drug
Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg
B group Purinostat Mesylate 15mg/m2Drug
Purinostat Mesylate 15mg/m2 + Tislelizumab 200mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective remission rate (ORR)Time frame: Up to week 96
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guanzhou, Guangzhou, China · Recruiting
West China hospital of Sichuan university
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.